Island engages advisers to advance biodefence strategy
Filed with ASX · · 2 pages · English
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- FDA agrees Animal Rule pathway and PRV eligibility
- FDA confirms response timing for Galidesivir
- US FDA Type C meeting briefing document submitted
- FDA Meeting request granted
- FDA meeting request lodged for Galidesivir
Later from Island Pharmaceuticals
- Coalition acceptance to advance US procurement & stockpiling
- Options exercised raises $1million
- Additional FDA Submission completed for Galidesivir
- Island expands Galidesivir IP with US Patent Grant
- Agreement with Texas Biomed for Galidesivir Program
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals